Skip to main content
. 2015 Dec 12;8:86. doi: 10.1186/s13041-015-0175-1

Fig. 1.

Fig. 1

Induction of CTA by a rotatory stimulus or intra-vestibular nuclei microinjection of AVP and the effects of the V1bR antagonist (n = 10). a, indication of the microinjection area in the VN (Nissl staining). b, induction of CTA by AVP microinjection into the VN and the blocking effect of V1bR antagonist SSR149415. c, induction of CTA after rotatory stimulus and the blocking effect of SSR149415 microinjection into the VN. d, induction of CTA after AVP intraperitoneal injection (i.p.) and the blocking effect of SSR149415 microinjection into the VN. * P < 0.05, ** P < 0.01, vs. vehicle; # P < 0.05, ## P < 0.01 vs. AVP 10 ng or 30 ng groups, respectively; Δ P < 0.05, vs. AVP (i.p.) used alone